<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Humans and mice with deficiency of the alpha2 subunit of the basement membrane protein laminin-2/merosin suffer from merosin-deficient <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> (MCMD) </plain></SENT>
<SENT sid="1" pm="."><plain>We have expressed a human laminin alpha2 chain transgene under the regulation of a muscle-specific <z:chebi fb="2" ids="16919">creatine</z:chebi> kinase promoter in mice with complete or partial deficiency of merosin </plain></SENT>
<SENT sid="2" pm="."><plain>The transgene restores the synthesis and localization of merosin in skeletal muscle, and greatly improves muscle <z:mp ids='MP_0000002'>morphology</z:mp> and integrity and the health and longevity of the mice </plain></SENT>
<SENT sid="3" pm="."><plain>However, the transgenic mice share with the nontransgenic dystrophic mice a progressive <z:e sem="disease" ids="C1456822,C0311395" disease_type="Disease or Syndrome;Finding" abbrv="">lameness</z:e> of hind legs, suggestive of a nerve defect </plain></SENT>
<SENT sid="4" pm="."><plain>These results indicate that the absence of merosin in tissues other than the muscle, such as <z:mp ids='MP_0008912'>nervous</z:mp> tissue, is a critical component of MCMD </plain></SENT>
<SENT sid="5" pm="."><plain>Future gene therapies of human MCMD, and perhaps of other forms of <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo>, may require restoration of the defective gene product in multiple tissues </plain></SENT>
</text></document>